Stonepine Capital Management’s MaxCyte MXCT Stock Holding History

Stonepine Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$706K	Buy	1,004,673 +535,655	+114%	+$500K	0.28%	47
2025 Q4	$727K	Buy	469,018 +10,000	+2%	+$16K	0.53%	43
2025 Q3	$725K	Buy	+459,018	New	+$798K	0.59%	32
2023 Q4	–	Sell	-3,761,640	Closed	-$11.7M	–	20
2023 Q3	$11.7M	Sell	3,761,640 -205,276	-5%	-$825K	3.9%	7
2023 Q2	$18.2M	Buy	3,966,916 +1,259,826	+47%	+$5.79M	6.57%	6
2023 Q1	$13.4M	Buy	2,707,090 +2,433,803	+891%	+$12M	4.49%	7
2022 Q4	$1.49M	Buy	+273,287	New	+$1.68M	0.63%	16

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $88.9M AUM

Stonepine Capital Management's MXCT Position: Q1 2026 in Review

Stonepine Capital Management increased its MaxCyte (MXCT) stake by 114% in Q1 2026, buying an estimated $500K and bringing the position to 1,004,673 shares worth $706K. The position accounts for 0.28% of the portfolio, ranked #47.

Stonepine Capital Management first reported a position in MXCT in Q4 2022 and has held it in 7 quarters since. The position peaked at $18.2M in Q2 2023. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

Stonepine Capital Management held 1,004,673 shares of MaxCyte worth $706K as of Q1 2026.
Stonepine Capital Management bought 535,655 MaxCyte shares in Q1 2026, an estimated $500K.
MaxCyte made up 0.28% of Stonepine Capital Management's portfolio in Q1 2026, its #47 holding.
Stonepine Capital Management first reported a position in MaxCyte in Q4 2022 and has held it in 7 quarters since.
Stonepine Capital Management's MaxCyte position peaked at $18.2M in Q2 2023.
130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.